MPLT Stock Analysis: Buy, Sell, or Hold?
$28.34
1.00 (3.66%)
▲
5d:
-4.09%
30d:
-0.94%
90d:
+57.23%
BUY
HIGH Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Jun 25, 2026
20d
Get Alerted When MPLT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MPLT shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: MPLT shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: MPLT is currently trading at $28.34, which is considered slightly low relative to its 30-day fair value range of $27.93 to $30.44.
Technical Outlook: Technically, MPLT is in a strong uptrend. Immediate support is located at $25.52, while resistance sits at $30.82. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (6th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $37.90 (+33.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MPLT is in a strong uptrend. Immediate support is located at $25.52, while resistance sits at $30.82. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (6th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $37.90 (+33.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$27.93 -
$30.44
Company Quality Score
56/100
(HOLD)
Options IV Signal
6th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
90.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 6th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 33.7% below Wall St target ($37.90)
Trading Range Analysis
30-Day Trading Range
$27.93 -
$30.44
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$8.88
(31.3%)
Support & Resistance Levels
Support Level
$25.52
Resistance Level
$30.83
Current Trend
Strong Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.35
Wall Street Target
$37.90
(+33.7%)
Share & Embed Analysis
Last updated: June 03, 2026 7:40 PM ET
Data refreshes hourly during market hours. Next update: 8:40 PM
Data refreshes hourly during market hours. Next update: 8:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MPLT showing a specific setup today?
Insider Activity (6 Months)
4
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Robert C Malenka
SELL
736 shares
2026-02-24
Robert C Malenka
SELL
11264 shares
2026-02-23
George Pavlov
BUY
9920 shares
2026-02-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |